ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Clinical Response"

  • Abstract Number: 2538 • 2016 ACR/ARHP Annual Meeting

    Comparison of Intravenous Versus Subcutaneous Abatacept for the Treatment of Rheumatoid Arthritis in a Routine Clinical Care Setting: A Preliminary, Time to Response Analysis

    Christopher J. Swearingen, Jessica Poon, Hannah Bernstein and Yusuf Yazici, Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY

    Background/Purpose: With the availability of multiple biologic agents, each with different modes of action, use of real world registries provide the manner in which to…
  • Abstract Number: 2758 • 2016 ACR/ARHP Annual Meeting

    Minimal Disease Activity Among Psoriatic Arthritis Patients in Canada: Which Unmet Criteria Are More Prevalent Among Responders?

    J. Antonio Avina-Zubieta1, Andrew Chow2, Philip Baer3, John Kelsall4, Proton Rahman5, Jacqueline Stewart6, Boulos Haraoui7, Michel Zummer8, Emmanouil Rampakakis9, Eliofotisti Psaradellis10, Francois Nantel11, Karina Maslova12, Cathy Tkaczyk13, Brendan Osborne13 and Allen J Lehman12, 1Arthritis Research Canada, Richmond, BC, Canada, 2Credit Valley Rheumatology, Mississauga, ON, Canada, 3Independent Rheumatology Practice, Scarborough, ON, Canada, 4Rheumatology, University of British Columbia, Vancouver, BC, Canada, 5Rheumatology, St Claires Mercy Hospital, St Johns, NF, Canada, 6Penticton Regional Hospital, Penticton, BC, Canada, 7University of Montreal, Montreal, QC, Canada, 8Rheumatology, Ch Maisonneuve-Rosemont, Montreal, QC, Canada, 9JSS Medical Research, St-Laurent, QC, Canada, 10JSS Medical Research, Montreal, QC, Canada, 1119 Green belt Dr, Janssen Inc., Toronto, ON, Canada, 12Janssen Inc., Toronto, ON, Canada, 13Medical Affairs, Janssen Inc., Toronto, ON, Canada

    Background/Purpose: Minimal disease activity (MDA) is now considered an objective target which is more attainable in psoriatic arthritis (PsA) compared to remission (DAS28 <2.6) which…
  • Abstract Number: 2824 • 2016 ACR/ARHP Annual Meeting

    Lack of Partial Renal Response By 12 Weeks after Induction Therapy Is an Indicator to Switch the Treatment in Lupus Nephritis Class III or IV for Reducing Future Damage Accrual

    Hironari Hanaoka1, Hidehiro Yamada2, Tomofumi Kiyokawa3, Harunobu Iida1, Takeshi Suzuki1, Yoshioki Yamasaki4, Seido Ooka5, Hiroko Nagafuchi3, Takahiro Okazaki3, Daisuke Ichikawa6, Sayuri Shirai6, Yugo Shibagaki7, Junki Koike8 and Shoichi Ozaki3, 1Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, 2Rheumatology, Seirei Yokohama Hospital, Yokohama, Japan, 3Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, 4Internal Medicie, St. Marianna University School of Medicine, Kawasaki, Japan, 5Division of Rheumatology and Allergy, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, 6Division of Nephrology and Hypertension, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, 7Division of Nephrology and Hypertension, Department of Internal Medicine, St. Marianna University School of Medicine, K, Japan, 8Department of Pathology, St. Marianna University School of Medicine, Kawasaki, Japan

    Background/Purpose: Lupus nephritis (LN) class III or IV is associated with a poor prognosis for both patient and renal survival. The guideline or recommendation for…
  • Abstract Number: 2920 • 2016 ACR/ARHP Annual Meeting

    The Effect of Rituximab on B Cells in Skin and Peripheral Blood in Systemic Sclerosis

    Maaike Boonstra1, Annemarie L. Dorjée1, Koen D. Quint2, Tom W.J. Huizinga1, Hans U. Scherer3 and Jeska K. de Vries-Bouwstra1, 1Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 2Dermatology, Leiden University Medical Center, Leiden, Netherlands, 3Rheumatology, Leiden University Medical Center, Leiden, Netherlands

    Background/Purpose: Open-label studies provided evidence for possible efficacy of rituximab (RTX) in systemic sclerosis (SSc). Previously, we reported on a randomized placebo-controlled clinical trial in…
  • Abstract Number: 300 • 2016 ACR/ARHP Annual Meeting

    Mindfulness Predicts Treatment Response from Non-Pharmacological Therapy in Knee Osteoarthritis

    Augustine Lee1, Lori Lyn Price2, Xingyi Han3, Mei Chung4, William F. Harvey1, Jeffrey Driban5, Timothy E. McAlindon6 and Chenchen Wang1, 1Rheumatology, Tufts Medical Center, Boston, MA, 2Clinical Care Research, Tufts Medical Center, Boston, MA, 3Public Health and Community Medicine, Tufts University, Boston, MA, 4Department of Public Health and Community Medicine, Tufts University School of Medicine, Boston, MA, 5Tufts Medical Center, Boston, MA, 6Division of Rheumatology, Tufts Medical Center, Boston, MA

    Background/Purpose: Mindfulness is the ability to maintain a heightened awareness of one's moment-to-moment experiences without judging or reacting. Recent evidence suggests that mindfulness may improve…
  • Abstract Number: 3153 • 2016 ACR/ARHP Annual Meeting

    Automated Cell Phone Monitoring of Disease Activity and Medication Adherence in Early Rheumatoid Arthritis

    Laura Kuusalo1,2, Hannu Kautiainen3, Tuulikki Sokka-Isler4, Toini Uutela5, Laura Pirilä2, Timo Yli-Kerttula6, Markku J Kauppi7,8, Tuomas Rannio9, Kirsi Paalanen10, Arto Kokko9, Juha Asikainen9, Jelena Borodina10, Johanna Paltta2, Kari Laiho11, Andrus Mullanmaa12, Kari Puolakka12 and SandRA Study Group, 1University of Turku, Turku, Finland, 2Turku University Hospital, Turku, Finland, 3Unit of Primary Health Care, University of Helsinki and Helsinki University Hospital, Helsinki, Finland, 4Rheumatology, Jyvaskyla Central Hospital, Jyvaskyla, Finland, 5Lapland Central Hospital, Rovaniemi, Finland, 6Sairaalantie 3, Satakunta Central Hospital, Rauma, Finland, 7School of Medicine, University of Tampere, Tampere, Finland, 8Department of Rheumatology, Päijät-Häme Central Hospital, Lahti, Finland, 9Jyvaskyla Central Hospital, Jyväskylä, Finland, 10Jyvaskyla Central Hospital, Jyvaskyla, Finland, 11Päijät-Häme Central Hospital, Lahti, Finland, 12South Karelia Central Hospital, Lappeenranta, Finland

    Background/Purpose: Remission targeted treatment of early RA requires frequent monitoring. However, in clinical practice monitoring frequency is not always optimal due to factors like limited…
  • Abstract Number: 607 • 2016 ACR/ARHP Annual Meeting

    The Clinical Response to Biologic and Non-Biologic Disease Modifying Antirheumatic Drugs (DMARDs) According to Gender in a French-Canadian Population with Rheumatoid Arthritis (RA)

    Sonia Lagacé1, Louis Bessette2,3, Louis Coupal4 and Denis Choquette4, 1Medicine, Laval University, Quebec, QC, Canada, 2Rheumatology, Laval University, Québec, QC, Canada, 3Rhumatologie, CHU de Québec - Université Laval, Quebec, QC, Canada, 4Rheumatology, Institut de Recherche en Rhumatologie de Montréal (IRRM), Montréal, QC, Canada

    Background/Purpose: Several studies have reported that women with RA had higher level of pain, disease activity and functional impairment compared to men. In addition, women…
  • Abstract Number: 745 • 2016 ACR/ARHP Annual Meeting

    Clinical and Laboratory Correlates of Response in a Phase 3 Clinical Trial of Belimumab or Placebo Administered Subcutaneously Plus Standard Care to Patients with Systemic Lupus Erythematosus (SLE)

    Ronald F. van Vollenhoven1, William Stohl2, Richard Furie3, Norma Lynn Fox4, James Groark5, Damon Bass5, Milena Kurtinecz5, Bonnie Pobiner6, William Eastman6, Tania Gonzalez-Rivera5 and David Gordon5, 1Department of Clinical Immunology & Rheumatology, Amsterdam Rheumatology and Immunology Center ARC, Amsterdam, Netherlands, 2Division of Rheumatology, University of Southern California Keck School of Medicine, Los Angeles, CA, 3Division of Rheumatology, Northwell Health, Great Neck, NY, 4GSK, Potomac, MD, 5GSK, Philadelphia, PA, 6GSK, Research Triangle Park, NC

    Background/Purpose: The SRI (SLE responder index) is a composite measure established as a primary endpoint in SLE clinical trials. However, it has been questioned whether…
  • Abstract Number: 1044 • 2016 ACR/ARHP Annual Meeting

    Treatment with Tofacitinib Is Associated with Clinically Meaningful Reductions in Axial MRI Inflammation in Patients with Ankylosing Spondylitis

    Walter Maksymowych1, Désirée van der Heijde2, Xenofon Baraliakos3, Atul A. Deodhar4, Matt Brown5, Sarah Sherlock6, David Li7, Dona Fleishaker8 and Thijs Hendrikx7, 1Department of Medicine, University of Alberta, Edmonton, AB, Canada, 2Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 3Rheumazentrum Ruhrgebiet, Herne, Germany, 4Division of Arthritis and Rheumatic Diseases, Oregon Health and Science University, Portland, OR, 5Institute for Health and Biomedical Innovation, Queensland University of Technology, Brisbane, Australia, 6Pfizer Inc, Cambridge, MA, 7Pfizer Inc, Collegeville, PA, 8Pfizer Inc, Groton, CT

    Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor. Minimum clinically important differences (MCID) for SPondyloArthritis Research Consortium of Canada (SPARCC) MRI SI joint and spine…
  • Abstract Number: 1051 • 2016 ACR/ARHP Annual Meeting

    Determining the Minimal Clinically Important Difference for Improvement for Systemic Lupus Erythematosus Disease Activity Index-2000 Responder Index-50 (S2K RI-50)

    Zahi Touma1, Dafna D Gladman2, Dorcas Beaton3, Jiandong Su4 and Murray Urowitz1, 1Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 2University of Toronto, Toronto, ON, Canada, 3Mobility Program Clinical Research Unit, St Michael's Hospital, Toronto, ON, Canada, 4Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada

    Background/Purpose: Systemic Lupus Erythematosus Disease Activity Index-2000 Responder Index-50 (S2K RI-50) is a reliable and valid index able to measure ≥ 50% improvement in disease…
  • Abstract Number: 1258 • 2016 ACR/ARHP Annual Meeting

    Female Gender Is Associated with a Poorer Response to TNF-Inhibitors in Ankylosing Spondylitis

    T. Rusman1, M. Nurmohamed2, J.C. van Denderen3, I. Visman4 and I.E. Van der Horst - Bruinsma2, 1Rheumatology, VU University medical centre, Amsterdam, Netherlands, 2Amsterdam Rheumatology immunology Center |Departments of Rheumatology VU University Medical Center & Reade, Amsterdam, Netherlands, 3Center for Rheumatology and Rehabilitation, Jan van Breemen Institute, Amsterdam, Netherlands, 4Amsterdam Rheumatology and Immunology Center, VUmc and Reade, Amsterdam, Netherlands

    Background/Purpose: Limited data is available on the influence of smoking, Body Mass Index (BMI) and gender on disease activity and response to TNF inhibitors in…
  • Abstract Number: 1583 • 2016 ACR/ARHP Annual Meeting

    Body Mass Index Does Not Affect Response to Subcutaneous or Intravenous Abatacept in Patients with Rheumatoid Arthritis  

    MA D'Agostino1, R Alten2, E Mysler3, M Le Bars4, J Ye5, B Murthy5, J Heitzmann6, R Vadanici4 and G Ferraccioli7, 1Hôpital Ambroise Paré, Boulogne-Billancourt, France, 2Schlosspark-Klinik University Medicine, Berlin, Germany, 3Organización Médica de Investigación, Buenos Aires, Argentina, 4Bristol-Myers Squibb, Rueil-Malmaison, France, 5Bristol-Myers Squibb, Princeton, NJ, 6Excelya, Boulogne-Billancourt, France, 7Catholic University of the Sacred Heart, Rome, Italy

    Background/Purpose: High BMI is associated with reduced remission rates with anti-TNF agents in RA.1,2 In ACQUIRE (NCT00559585), SC and IV abatacept (ABA) achieved similar ACR20…
  • Abstract Number: 475 • 2015 ACR/ARHP Annual Meeting

    Benefits of Achieving Comprehensive Disease Control (CDC) in Patients with Rheumatoid Arthritis: Evidence from the Corrona Registry

    Arthur Kavanaugh1, Carol J. Etzel2,3, Wendi Malley3, Chitra Karki3, Jeffrey D. Greenberg3,4, Yanjun Bao5, Naijun Chen5 and Vishvas Garg6, 1University of California, San Diego School of Medicine, LaJolla, CA, 2The University of Texas MD Anderson Cancer Center, Houston, TX, 3Corrona, LLC, Southborough, MA, 4NYU School of Medicine, New York, NY, 5AbbVie Inc., North Chicago, IL, 6AbbVie, North Chicago, IL

    Background/Purpose: Based on international task force recommendations, the primary goal of rheumatoid arthritis (RA) treatment is to: achieve control of symptoms to greatest extent possible,…
  • Abstract Number: 609 • 2015 ACR/ARHP Annual Meeting

    A Reduction in Serum Uric Acid Levels May be Related to Methotrexate Efficacy in Early Rheumatoid Arthritis: Data from a Canadian Arthritis Cohort

    Jason Lee1, VP Bykerk2, George Dresser3, Gilles Boire4, Boulos Haraoui5, Carol Hitchon6, J Carter Thorne2, Diane Tin7, Shahin Jamal8, Edward C. Keystone9, Janet E. Pope10 and CATCH Investigators, 1Rheumatology, Western University, St. Joseph's Hospital, London, ON, Canada, 2University of Toronto, Toronto, ON, Canada, 3Clinical Pharmacology and Toxicology, Western University, London, ON, Canada, 4Department of Medicine/Division of Rheumatology, Université de Sherbrooke, Sherbrooke, QC, Canada, 5Institut de Rhumatologie, Montreal, QC, Canada, 6University of Manitoba, Winnipeg, MB, Canada, 7The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, 8Vancouver Coastal Health, Vancouver, BC, Canada, 9Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, 10Monsignor Roney Bldg/Rheum, University of Western Ontario, St Joseph Health Care, London, ON, Canada

    Background/Purpose: The mechanism of methotrexate in rheumatoid arthritis (RA) is complex. It may increase adenosine levels by blocking conversion to of xanthine to uric acid…
  • Abstract Number: 618 • 2015 ACR/ARHP Annual Meeting

    The Multi-Biomarker Disease Activity Score in Methotrexate Incomplete Responders Predicts Clinical Responses to Non-Biological Versus Biological Therapy in Early RA

    Karen Hambardzumyan1, Rebecca J. Bolce2, Saedis Saevarsdottir3, Kristina Forslind4,5, Johan A Karlsson6 and Ronald F. van Vollenhoven1, 1Department of Medicine, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden, 2Crescendo Bioscience Inc., South San Francisco, CA, 3Department of Medicine, Rheumatology Unit, The Karolinska Institute and Karolinska University Hospital, Stockholm, Sweden, 4Department of Medicine, Helsingborgs Lasarett, Section of Rheumatology, Helsingborg, Sweden, 5Departments of Rheumatology, Helsingborgs Hospital and University of Lund, Helsingborg and Lund, Sweden, 6Section of Rheumatology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden

    Background/Purpose: The Swedish Farmacotherapy (SWEFOT) trial and other trials in rheumatoid arthritis (RA) demonstrated that in MTX incomplete responder patients (MTX-IR) the addition of anti-TNF…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology